Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Associated Therapies: -

Clinical Trials

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

Phase 2

Completed

Conditions: Bladder Outlet Obstruction
Lower Urinary Tract Symptoms

Interventions: Drug: Placebo to solifenacin
Drug: solifenacin succinate
Drug: Placebo to tamsulosin
Drug: tamsulosin hydrochloride

First Posted Date: 2007-07-26

Last Posted Date: 2014-08-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 222

Registration Number: NCT00507455

Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Phase 2

Conditions: Upper Tract Ureterolithiasis

First Posted Date: 2007-05-25

Last Posted Date: 2007-05-25

Lead Sponsor: Hadassah Medical Organization

Registration Number: NCT00478998

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

Phase 2

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: UK-369,003
Drug: Tamsulosin

First Posted Date: 2007-04-06

Last Posted Date: 2018-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 609

Registration Number: NCT00457457

Locations: 🇬🇧
Pfizer Investigational Site, Bristol, United Kingdom

The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

Phase 4

Conditions: Renal Colic

First Posted Date: 2007-03-22

Last Posted Date: 2012-07-12

Lead Sponsor: Soroka University Medical Center

Target Recruit Count: 120

Registration Number: NCT00451061

Locations: 🇮🇱
Urology department, Soroka university medical center, Beer-Sheva, p,o,box 151, Israel

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

Not Applicable

Completed

Conditions: Kidney Stones
Ureteral Stones

Interventions: Drug: Placebo
Drug: Tamsulosin

First Posted Date: 2007-03-15

Last Posted Date: 2016-10-12

Lead Sponsor: Robert Swor

Target Recruit Count: 127

Registration Number: NCT00448123

Locations: 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States

Tamsulosin for Urolithiasis in the Emergency Dept

Phase 4

Completed

Conditions: Ureterolithiases

Interventions: Other: Placebo
Drug: tamsulosin

First Posted Date: 2006-09-29

Last Posted Date: 2018-12-10

Lead Sponsor: Andrew Meltzer

Target Recruit Count: 512

Registration Number: NCT00382265

Locations: 🇺🇸
The George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 1 locations